Silica Coated Paclitaxel Nanocrystals Enable Neural Stem Cell Loading For Treatment of Ovarian Cancer.


Journal

Bioconjugate chemistry
ISSN: 1520-4812
Titre abrégé: Bioconjug Chem
Pays: United States
ID NLM: 9010319

Informations de publication

Date de publication:
15 05 2019
Historique:
pubmed: 6 3 2019
medline: 18 2 2020
entrez: 6 3 2019
Statut: ppublish

Résumé

Ovarian cancer is commonly diagnosed only after it has metastasized to the abdominal cavity (stage III). While the current standard of care of intraperitoneal (IP) administration of cisplatin and paclitaxel (PTX) combination chemotherapy has benefit, patient 5-year survival rates are low and have not significantly improved in the past decade. The ability to target chemotherapy selectively to ovarian tumors while sparing normal tissue would improve efficacy and decrease toxicities. We have previously shown that cisplatin-loaded nanoparticles (NPs) loaded within neural stem cells (NSCs) are selectively delivered to ovarian tumors in the abdominal cavity following IP injection, with no evidence of localization to normal tissue. Here we extended the capabilities of this system to also include PTX delivery. NPs that will be loaded into NSCs must contain a high amount of drug by weight but constrain the release of the drug such that the NSCs are viable after loading and can successfully migrate to tumors. We developed silica coated PTX nanocrystals (Si[PTX-NC]) meeting these requirements. Si[PTX-NC] were more effective than uncoated PTX-NC or Abraxane for loading NSCs with PTX. NSCs loaded with Si[PTX-NC] maintained their migratory ability and, for low dose PTX, were more effective than free PTX-NC or Si[PTX-NC] at killing ovarian tumors in vivo. This work demonstrates that NSC/NP delivery is a platform technology amenable to delivering different therapeutics and enables the pursuit of NSC/NP targeted delivery of the entire preferred chemotherapy regimen for ovarian cancer. It also describes efficient silica coating chemistry for PTX nanocrystals that may have applications beyond our focus on NSC transport.

Identifiants

pubmed: 30835443
doi: 10.1021/acs.bioconjchem.9b00160
pmc: PMC9070965
mid: NIHMS1801670
doi:

Substances chimiques

Antineoplastic Agents, Phytogenic 0
Silicon Dioxide 7631-86-9
Paclitaxel P88XT4IS4D

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1415-1424

Subventions

Organisme : NCI NIH HHS
ID : P30 CA033572
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA197359
Pays : United States

Références

J Nanomed Nanotechnol. 2013 Feb 18;4(2):1000164
pubmed: 24163786
J Control Release. 2014 Oct 10;191:82-9
pubmed: 24952368
Bioconjug Chem. 2017 Jun 21;28(6):1767-1776
pubmed: 28453256
Stem Cells. 2012 Feb;30(2):314-25
pubmed: 22084033
Sci Transl Med. 2013 May 8;5(184):184ra59
pubmed: 23658244
Nano Lett. 2007 Dec;7(12):3759-65
pubmed: 17979310
Nanomedicine (Lond). 2015;10(16):2537-52
pubmed: 26293310
J Pharm Sci. 2010 Mar;99(3):1288-98
pubmed: 19743504
Int J Pharm. 2010 May 10;390(2):242-9
pubmed: 20167270
Small. 2013 Dec 20;9(24):4123-9
pubmed: 23873826
Mol Pharm. 2010 Jun 7;7(3):863-9
pubmed: 20420443
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 May;10(3):e1499
pubmed: 29044971
Nanomedicine (Lond). 2007 Aug;2(4):415-23
pubmed: 17716129
Sci Transl Med. 2015 Jun 10;7(291):291ra94
pubmed: 26062846
Colloids Surf B Biointerfaces. 2014 Jan 1;113:43-50
pubmed: 24060929
Nat Med. 2010 Sep;16(9):1035-41
pubmed: 20711198
Ann Oncol. 2016 Apr;27 Suppl 1:i58-i62
pubmed: 27141074
ACS Nano. 2011 Sep 27;5(9):7462-70
pubmed: 21854047
Clin Cancer Res. 2017 Jun 15;23(12):2951-2960
pubmed: 27979915
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:126-138
pubmed: 28027849
Nanoscale. 2015 Jun 28;7(24):10790-800
pubmed: 26038337
Gene Ther. 2008 May;15(10):739-52
pubmed: 18369324
Mol Pharm. 2015 May 4;12(5):1485-500
pubmed: 25799282
Am J Pathol. 2010 Sep;177(3):1053-64
pubmed: 20651229
Oncotarget. 2011 May;2(5):368-77
pubmed: 21576762

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH